Cargando…
The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro
BACKGROUND: Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226008/ https://www.ncbi.nlm.nih.gov/pubmed/37082911 http://dx.doi.org/10.1177/08853282231171681 |
_version_ | 1785050496201916416 |
---|---|
author | Fuchs, Benedikt Birt, Alexandra Moellhoff, Nicholas Kuhlmann, Constanze Giunta, Riccardo Wiggenhauser, Paul Severin |
author_facet | Fuchs, Benedikt Birt, Alexandra Moellhoff, Nicholas Kuhlmann, Constanze Giunta, Riccardo Wiggenhauser, Paul Severin |
author_sort | Fuchs, Benedikt |
collection | PubMed |
description | BACKGROUND: Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects of fibrin glue on the cell-molecular level. This study examines the effects of fibrin glue on angiogenesis and lymphangiogenesis, as well as adipose-derived stem cells (ASCs) with a focus on gene and protein expression in scaffolds regularly used for tissue engineering approaches. METHODS: Collagen-based dermal regeneration matrices (DRM) were seeded with human umbilical vein endothelial cells (HUVEC), human dermal lymphatic endothelial cells (LECs), or adipose-derived stem cells (ASC) and fixed with or without fibrin glue according to the experimental group. Cultures were maintained for 1 and 7 days. Finally, angiogenic and lymphangiogenic gene and protein expression were measured with special regard to subtypes of vascular endothelial growth factor (VEGF) and corresponding receptors using Multiplex-qPCR and ELISA assays. In addition, the hypoxia-induced factor 1-alpha (HIF1a) mediated intracellular signaling pathways were included in assessments to analyze a hypoxic encapsulating effect of fibrin polymers. RESULTS: All cell types reacted to fibrin glue application with an alteration of gene and protein expression. In particular, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth receptor 1 (VEGFR1/FLT1), vascular endothelial growth receptor 2 (VEGFR2/KDR), vascular endothelial growth receptor 3 (VEGFR3/FLT4) and Prospero Homeobox 1 (PROX1) were depressed significantly depending on fibrin glue. Especially short-term fibrin effect led to a continuous downregulation of respective gene and protein expression in HUVECs, LECs, and ASCs. CONCLUSION: Our findings demonstrate the impact of fibrin glue application in dermal regeneration with special regard to angiogenesis and lymphangiogenesis. In particular, a short fibrin treatment of 24 hours led to a decrease in gene and protein levels of LECS, HUVECs, and ASCs. In contrast, the long-term application showed less effect on gene and protein expressions. Therefore, this work demonstrated the negative effects of fibrin-treated cells in tissue engineering approaches and could affect wound healing during dermal regeneration. |
format | Online Article Text |
id | pubmed-10226008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-102260082023-05-30 The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro Fuchs, Benedikt Birt, Alexandra Moellhoff, Nicholas Kuhlmann, Constanze Giunta, Riccardo Wiggenhauser, Paul Severin J Biomater Appl Soft Tissues and Materials BACKGROUND: Commercial fibrin glue is increasingly finding its way into clinical practice in surgeries to seal anastomosis, and initiate hemostasis or tissue repair. Human biological glue is also being discussed as a possible cell carrier. To date, there are only a few studies addressing the effects of fibrin glue on the cell-molecular level. This study examines the effects of fibrin glue on angiogenesis and lymphangiogenesis, as well as adipose-derived stem cells (ASCs) with a focus on gene and protein expression in scaffolds regularly used for tissue engineering approaches. METHODS: Collagen-based dermal regeneration matrices (DRM) were seeded with human umbilical vein endothelial cells (HUVEC), human dermal lymphatic endothelial cells (LECs), or adipose-derived stem cells (ASC) and fixed with or without fibrin glue according to the experimental group. Cultures were maintained for 1 and 7 days. Finally, angiogenic and lymphangiogenic gene and protein expression were measured with special regard to subtypes of vascular endothelial growth factor (VEGF) and corresponding receptors using Multiplex-qPCR and ELISA assays. In addition, the hypoxia-induced factor 1-alpha (HIF1a) mediated intracellular signaling pathways were included in assessments to analyze a hypoxic encapsulating effect of fibrin polymers. RESULTS: All cell types reacted to fibrin glue application with an alteration of gene and protein expression. In particular, vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC), vascular endothelial growth receptor 1 (VEGFR1/FLT1), vascular endothelial growth receptor 2 (VEGFR2/KDR), vascular endothelial growth receptor 3 (VEGFR3/FLT4) and Prospero Homeobox 1 (PROX1) were depressed significantly depending on fibrin glue. Especially short-term fibrin effect led to a continuous downregulation of respective gene and protein expression in HUVECs, LECs, and ASCs. CONCLUSION: Our findings demonstrate the impact of fibrin glue application in dermal regeneration with special regard to angiogenesis and lymphangiogenesis. In particular, a short fibrin treatment of 24 hours led to a decrease in gene and protein levels of LECS, HUVECs, and ASCs. In contrast, the long-term application showed less effect on gene and protein expressions. Therefore, this work demonstrated the negative effects of fibrin-treated cells in tissue engineering approaches and could affect wound healing during dermal regeneration. SAGE Publications 2023-04-21 2023-05 /pmc/articles/PMC10226008/ /pubmed/37082911 http://dx.doi.org/10.1177/08853282231171681 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Soft Tissues and Materials Fuchs, Benedikt Birt, Alexandra Moellhoff, Nicholas Kuhlmann, Constanze Giunta, Riccardo Wiggenhauser, Paul Severin The use of commercial fibrin glue in dermal replacement material reduces angiogenic and lymphangiogenic gene and protein expression in vitro |
title | The use of commercial fibrin glue in dermal replacement material
reduces angiogenic and lymphangiogenic gene and protein expression in
vitro |
title_full | The use of commercial fibrin glue in dermal replacement material
reduces angiogenic and lymphangiogenic gene and protein expression in
vitro |
title_fullStr | The use of commercial fibrin glue in dermal replacement material
reduces angiogenic and lymphangiogenic gene and protein expression in
vitro |
title_full_unstemmed | The use of commercial fibrin glue in dermal replacement material
reduces angiogenic and lymphangiogenic gene and protein expression in
vitro |
title_short | The use of commercial fibrin glue in dermal replacement material
reduces angiogenic and lymphangiogenic gene and protein expression in
vitro |
title_sort | use of commercial fibrin glue in dermal replacement material
reduces angiogenic and lymphangiogenic gene and protein expression in
vitro |
topic | Soft Tissues and Materials |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226008/ https://www.ncbi.nlm.nih.gov/pubmed/37082911 http://dx.doi.org/10.1177/08853282231171681 |
work_keys_str_mv | AT fuchsbenedikt theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT birtalexandra theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT moellhoffnicholas theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT kuhlmannconstanze theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT giuntariccardo theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT wiggenhauserpaulseverin theuseofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT fuchsbenedikt useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT birtalexandra useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT moellhoffnicholas useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT kuhlmannconstanze useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT giuntariccardo useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro AT wiggenhauserpaulseverin useofcommercialfibringlueindermalreplacementmaterialreducesangiogenicandlymphangiogenicgeneandproteinexpressioninvitro |